Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder in adults as monotherapy and as adjunctive therapy with lithium or valproate. NEW... | December 20, 2021